MISTER SPEX SE (MRX.DE) Fundamental Analysis & Valuation

FRA:MRX • DE000A3CSAE2

Current stock price

1.3 EUR
+0.02 (+1.17%)
Last:

This MRX.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MRX.DE Profitability Analysis

1.1 Basic Checks

  • In the past year MRX has reported negative net income.
  • In the past year MRX has reported a negative cash flow from operations.
  • In the past 5 years MRX always reported negative net income.
  • MRX had negative operating cash flow in 4 of the past 5 years.
MRX.DE Yearly Net Income VS EBIT VS OCF VS FCFMRX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

  • The Return On Assets of MRX (-45.56%) is worse than 90.74% of its industry peers.
  • MRX has a Return On Equity of -119.72%. This is amonst the worse of the industry: MRX underperforms 88.89% of its industry peers.
Industry RankSector Rank
ROA -45.56%
ROE -119.72%
ROIC N/A
ROA(3y)-27.31%
ROA(5y)-20%
ROE(3y)-57.09%
ROE(5y)-43%
ROIC(3y)N/A
ROIC(5y)N/A
MRX.DE Yearly ROA, ROE, ROICMRX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • With a decent Gross Margin value of 54.41%, MRX is doing good in the industry, outperforming 79.63% of the companies in the same industry.
  • MRX's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for MRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y0.94%
MRX.DE Yearly Profit, Operating, Gross MarginsMRX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. MRX.DE Health Analysis

2.1 Basic Checks

  • MRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, MRX has more shares outstanding
  • Compared to 5 years ago, MRX has more shares outstanding
  • MRX has a worse debt/assets ratio than last year.
MRX.DE Yearly Shares OutstandingMRX.DE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
MRX.DE Yearly Total Debt VS Total AssetsMRX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • MRX has an Altman-Z score of -2.45. This is a bad value and indicates that MRX is not financially healthy and even has some risk of bankruptcy.
  • MRX's Altman-Z score of -2.45 is on the low side compared to the rest of the industry. MRX is outperformed by 81.48% of its industry peers.
  • MRX has a Debt/Equity ratio of 0.81. This is a neutral value indicating MRX is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.81, MRX is not doing good in the industry: 62.96% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.81
Debt/FCF N/A
Altman-Z -2.45
ROIC/WACCN/A
WACC5.2%
MRX.DE Yearly LT Debt VS Equity VS FCFMRX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • MRX has a Current Ratio of 2.31. This indicates that MRX is financially healthy and has no problem in meeting its short term obligations.
  • MRX has a better Current ratio (2.31) than 85.19% of its industry peers.
  • A Quick Ratio of 1.66 indicates that MRX should not have too much problems paying its short term obligations.
  • With an excellent Quick ratio value of 1.66, MRX belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.31
Quick Ratio 1.66
MRX.DE Yearly Current Assets VS Current LiabilitesMRX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. MRX.DE Growth Analysis

3.1 Past

  • The earnings per share for MRX have decreased strongly by -26.68% in the last year.
  • MRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.95%.
  • MRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.25% yearly.
EPS 1Y (TTM)-26.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.09%
Revenue 1Y (TTM)-16.95%
Revenue growth 3Y3.73%
Revenue growth 5Y9.25%
Sales Q2Q%-17.78%

3.2 Future

  • Based on estimates for the next years, MRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.35% on average per year.
  • MRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.67% yearly.
EPS Next Y54.5%
EPS Next 2Y30.32%
EPS Next 3Y19.35%
EPS Next 5YN/A
Revenue Next Year-16.86%
Revenue Next 2Y-8.45%
Revenue Next 3Y-4.58%
Revenue Next 5Y11.67%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MRX.DE Yearly Revenue VS EstimatesMRX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
MRX.DE Yearly EPS VS EstimatesMRX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. MRX.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MRX. In the last year negative earnings were reported.
  • Also next year MRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRX.DE Price Earnings VS Forward Price EarningsMRX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRX.DE Per share dataMRX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • MRX's earnings are expected to grow with 19.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.32%
EPS Next 3Y19.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MRX.DE Dividend Analysis

5.1 Amount

  • No dividends for MRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MRX.DE Fundamentals: All Metrics, Ratios and Statistics

MISTER SPEX SE

FRA:MRX (4/2/2026, 7:00:00 PM)

1.3

+0.02 (+1.17%)

Chartmill FA Rating
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)11-13
Earnings (Next)N/A
Inst Owners19.53%
Inst Owner ChangeN/A
Ins Owners20.78%
Ins Owner ChangeN/A
Market Cap45.56M
Revenue(TTM)185.36M
Net Income(TTM)-68.92M
Analysts77.5
Price Target3.98 (206.15%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1%
Min Revenue beat(2)-1.02%
Max Revenue beat(2)-0.98%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.7%
PT rev (3m)-9.93%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.36%
EPS NY rev (3m)0.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.25
P/FCF N/A
P/OCF N/A
P/B 0.79
P/tB 0.84
EV/EBITDA N/A
EPS(TTM)-2.09
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS5.29
BVpS1.64
TBVpS1.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -45.56%
ROE -119.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.41%
FCFM N/A
ROA(3y)-27.31%
ROA(5y)-20%
ROE(3y)-57.09%
ROE(5y)-43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y0.94%
F-Score4
Asset Turnover1.23
Health
Industry RankSector Rank
Debt/Equity 0.81
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.61%
Cap/Sales 2.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.31
Quick Ratio 1.66
Altman-Z -2.45
F-Score4
WACC5.2%
ROIC/WACCN/A
Cap/Depr(3y)41.44%
Cap/Depr(5y)71.03%
Cap/Sales(3y)6.28%
Cap/Sales(5y)7.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-26.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.09%
EPS Next Y54.5%
EPS Next 2Y30.32%
EPS Next 3Y19.35%
EPS Next 5YN/A
Revenue 1Y (TTM)-16.95%
Revenue growth 3Y3.73%
Revenue growth 5Y9.25%
Sales Q2Q%-17.78%
Revenue Next Year-16.86%
Revenue Next 2Y-8.45%
Revenue Next 3Y-4.58%
Revenue Next 5Y11.67%
EBIT growth 1Y-29.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year98.45%
EBIT Next 3Y33.34%
EBIT Next 5Y29.96%
FCF growth 1Y50.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-711.8%
OCF growth 3YN/A
OCF growth 5YN/A

MISTER SPEX SE / MRX.DE Fundamental Analysis FAQ

What is the fundamental rating for MRX stock?

ChartMill assigns a fundamental rating of 2 / 10 to MRX.DE.


What is the valuation status for MRX stock?

ChartMill assigns a valuation rating of 0 / 10 to MISTER SPEX SE (MRX.DE). This can be considered as Overvalued.


What is the profitability of MRX stock?

MISTER SPEX SE (MRX.DE) has a profitability rating of 1 / 10.


What is the financial health of MISTER SPEX SE (MRX.DE) stock?

The financial health rating of MISTER SPEX SE (MRX.DE) is 3 / 10.